An interventional study of Resistance Training in Hypertrophy, Exercise Training and Skeletal Muscle Atrophy, sponsored by University of Jyvaskyla. Recruiting at 1 site in Finland. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-06.
Sponsored by University of Jyvaskyla · Not applicable, Interventional, and Basic science
The goals of our research project are to identify factors explaining inter-individual variation in responses to resistance training (RT) and the baseline determinants underlying an individual's sensitivity to respond to RT. Moreover, investigators aim to assess whether a responsiveness to RT predicts responsiveness to endurance training (ET). Thus, investigators aim to gain a deeper understanding of exercise adaptation processes. The main questions investigators aim to answer are:
To examine these main research questions, high (n=30), low (n=30), and moderate (n=30) responders of skeletal muscle growth in response to RT (intervention I, NCT05874986) are reallocated into a subsequent 12-week RT intervention (intervention II) after a detraining period. A subgroup of these participants (n=10) will engage in a 6-week control period before starting the second RT period. Additionally, after intervention II, participants will participate in an ET intervention, lasting 6 weeks.
In this intervention II, reallocated participants will be:
Furthermore, in the ET intervention, participants will be:
While the diverse health and performance benefits of resistance training (RT) are widely recognized, some individuals demonstrate notably divergent responses to RT intervention. This phenomenon is termed inter-individual response variation to RT. However, despite the prevalence of these research findings, the precise underlying mechanisms contributing to these differential RT responses remain ambiguous. Finally, it is currently unknown whether a responsiveness to RT predicts responsiveness to ET within the same set of participants, as this area of research is critically understudied.
Investigators aim to investigate the cellular, molecular, and neuromuscular mechanisms behind the plausible RT response variability intra- and inter-individually, using trial-to-trial, i.e. resistance training, detraining, and retraining design. Moreover, as the impact of diverse polygenic effects on RT responsiveness is yet to be determined, investigators will employ a multi-OMIC (genomic, epigenomic, transcriptomic, proteomic, and metabolomic) approach to unravel previously unknown denominators of RT responsiveness. Finally, numerous environmental factors, e.g. nutrition, stress, sleep, and physical activity are monitored during the study to assess the effects of non-physiological mechanisms on RT response variability.
In our study, 362 healthy male and female participants in total started in the study and were destined to undergo an RT period of 12 weeks in two separate periods (intervention I refers to NCT05874986). Then, a subset of the participants from intervention I will be reallocated into intervention II based on the magnitude increase of m. vastus lateralis (VL) cross-sectional area (CSA) assessed by ultrasound using extended-field-of-view mode. Similar to intervention I, intervention II will be performed in separate periods similarly to the data collection I and II of intervention I to first accumulate approximately 32 weeks of detraining for both cohorts, after which 12 weeks of RT is performed.
Moreover, a subset (n=30) of the participants aged 40-50 from intervention I not selected for intervention II have a chance to take part in a 10-week home training sub-study. These participants will be randomized to a non-training control group (n=15) and a home training group (n=15). The home training group will carry out a 10-week RT period utilizing muscle-strengthening activities in their home. This sub-study investigates how minimally supervised RT executed at home after supervised gym RT can maintain muscle strength and size compared to non-training. Home training is flexible, time-saving, and inexpensive. It is also done twice weekly using safe and effective training protocols and movements. Home-based training includes pistol squat, reverse nordic, push up, and bent-over row, and bicep curl exercises. To achieve progression, the total load will be increased by increasing the number of repetitions per set, and/or increasing the load by using a progression from easier to more difficult techniques and/or by adding resistance bands, which will be provided to participant's free of charge for the duration of the study. Participants will be contacted regularly to ensure motivation and adherence to home exercise. All the participants in this sub-study, as well as the other participants not selected for intervention II are offered a self-directed, non-supervised 7-week RT period with a similar design as in intervention I with access to our gym located in our Faculty's building. VL CSA, horizontal leg press 1 repetition maximum, and body composition will be assessed before and after home training and self-directed RT for each participant.
In intervention II, participants will be performing RT similarly to intervention I. However, for the last 5 weeks of the intervention, RT volume will be increased by 40 % for the lower body exercises to assess the impact of RT volume increment on RT responses. After 12 weeks of RT, an experimental RT session will be conducted to assess the acute physiological responses to resistance exercise. The experimental session will consist of five heavy sets of both horizontal leg press and leg extension exercises. During the last RT week, participants will engage in recovery measurements before and after the second-to-last and the last RT bout, and once during the days between these two bouts. After 12 weeks of RT, participants will be performing an additional acute resistance exercise session. All the participants NOT selected for intervention II are able to participate in a self-directed, 6-week RT period with measurements before and after this period. These measurements include body composition, muscle size (VL CSA and muscle thickness of elbow flexors) and muscle strength (dynamic 1RM of horizontal leg press and barbell scott curl) assessments. A subgroup of the participants (n=10) will engage in a control period of 6 weeks in duration, before the onset of RT.
After the intervention II, participants will begin a washout period lasting approximately 16 weeks (± 2), during which participants are advised to abstain from RT and ET. After a washout period, participants will participate in the familiarization measurements regarding the ET intervention. In familiarization, participants are measured with an electrocardiogram (ECG), after which a medical doctor will evaluate the resting ECG results to verify the eligibility of each participant. Moreover, participants will be habituated to movement economy testing by performing 3x3 min low-intervals with loads of 30-55-80 watts for females and 50-80-110 watts for males, respectively, and other included measurements. After familiarization and eligibility assessment, baseline measurements will be conducted the following week. Baseline measurements include body composition and volume assessment with a 3D optical body scanner, a 4 x 4 minute movement economy test with individualized, progressive loads determined in the familiarization (last load near the aerobic threshold). Movement economy intervals are performed with no rest in between. Finally, a maximal oxygen uptake (VO2max) will be measured breath-by-breath with an incremental RAMP test. The starting intensity will be 30 watts for both males and females, and the intensity will be increased by 30 and 25 watts per minute for males and females, respectively. The RAMP test will be performed with a self-selected cadence above 60 rounds per minute (rpm). When participants fail to maintain a cadence over 60 rpm second time, after one warning and despite heavy encouragement, the RAMP test will be terminated. All the testing will be performed using a bicycle ergometer. Heart rate, heart rate variability (HRV), expired gas analysis, arterial oxygen saturation, power output, stroke volume and cardiac output will be monitored continuously during the tests. Perceived exertion is assessed with a modified RPE scale of 0-10 after each movement economy interval and RAMP test. Blood lactate, blood glucose and hemoglobin concentrations are also measured after each movement economy interval and at the end of the RAMP test.
Endurance exercise is programmed based on the guidelines by the American College of Sports Medicine. During weeks 1-2, 45 minutes of low-intensity (= near the first ventilatory threshold) steady-state cycling is performed. In weeks 3-4, 50 minutes of cycling is performed, during which every other session includes low intensity cycling and every other session 3 x 10-minute intervals (with 4-minute rest after each interval) at moderate intensity (= between the first and the second ventilatory thresholds). Finally, in weeks 5-6, 55 minutes of cycling is performed, consisting of 4 x 10-minute intervals (with 3-minute rest after each interval) at a moderate intensity. Participants will be doing endurance exercises in groups of 2-4, and training three times a week at the standardized time of day. At the beginning of ET, appropriate training intensities are verified with blood lactate and the modified RPE scale. Training intensities at the start are decided by two blinded researchers based on the ventilatory thresholds obtained during the RAMP test. Individual training data, including heart rate, HRV, RPE, and wattage, is collected. The wattage is continuously displayed on the screen of the cycle ergometers during sessions to maintain appropriate training intensities. Wattage is increased within and between training sessions according to heart rate, lactate concentration, and modified RPE scale to establish progression. Before the onset of each interval session, a brief low-intensity steady-state warm-up of 7-8 minutes is performed.
In this study, investigators aim to identify several previously unknown molecular determinants that underlie the observed heterogeneity in RT responses. This could significantly increase the understanding of exercise physiology, which can be applied, e.g., in sports medicine, rehabilitation, and sports coaching. Moreover, this study can promote the development of personalized exercise prescriptions as part of health care. Indeed, it is vital to examine whether the same individuals respond similarly or differently to RT and ET at least in the short term. These findings can then be used to adjust individualized training programming not only as a part of health care but also regarding physical performance optimization. Finally, the findings of the study can operate as a foundational work for future research on the topic of RT response heterogeneity.
139 studies on the registry are indexed under Hypertrophy; 22 are open to participants now.
This study's planned enrollment of 90 is above the median of 34 across 112 interventional studies indexed under Hypertrophy.
Browse Hypertrophy studies →University of Jyvaskyla is the lead sponsor of 25 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group consists of participants with the highest increase in skeletal muscle hypertrophy of m. vastus lateralis in response to the initial 12 weeks of RT (Intervention I).
Other: Resistance Training
This group consists of participants with the moderate increase in skeletal muscle hypertrophy of m. vastus lateralis in response to the initial 12 weeks of RT (Intervention I).
Other: Resistance Training
This group consists of participants with the lowest increase in skeletal muscle hypertrophy of m. vastus lateralis in response to the initial 12 weeks of RT (Intervention I).
Other: Resistance Training
12-week resistance training
Also known as: Exercise Training
Change in m. vastus lateralis (VL) cross-sectional area (CSA) with ultrasound (US)
VL CSA (cm\^2) is determined at mid-thigh using a B-mode axial plane US (Venue Fit R4, GE Medical Systems, USA) with a L4-20t-RS linear-array probe (48,43 mm width) in extended-field-of-view mode (6/12 MHz, 39 frames per second). Additionally, VL CSA (cm\^2) will also be determined at baseline with different US, at mid-thigh using a B-mode axial plane US (model SSD-α10, Aloka, Tokyo, Japan) with a 13 MHz linear-array probe (60 mm width) in extended-field-of-view mode (23 Hz sampling frequency). Aloka-US was used in the intervention I, but GE-US in intervention II due to the progressive malfunctioning of Aloka. Therefore, both machines are used in baseline measurements to calculate the plausible inter-US variability. The CSA will be measured using the polygon function in ImageJ software. Per each measurement, three images will be analysed from which the average from the two closest ones will be calculated.
Time frame: Baseline (test and retest), week 7, week 13
Muscle protein synthesis (MPS) with the Combined Oral Stable Isotope Assessment of Muscle (COSIAM)
A baseline saliva sample is collected to determine the deuterium labelling of plasma proteins. Then, participants ingest 3ml/kg deuterium oxide (D2O, 70-Atom%) divided into three boluses and 1 ml/kg top-up dose twice a week throughout the MPS examination period. When muscle proteins are built, the accumulation of deuterium-labelled alanine amino acid in the VL can be used to measure local fractional sarcoplasmic, myofibrillar, mitochondrial, and collagen MPS rates via gas chromatography-pyrolysis-isotope ratio mass spectrometry (GC-Pyrolysis-IRMS). The outcome will be expressed as %/day. 30 mg of VL muscle biopsy is used for MPS analysis. To estimate alanine precursor enrichment (APE), saliva samples are collected before and after each D2O drink consumption and 24 and 48 hours after the 3 x bolus to monitor body water enrichment via thermal conversion elemental analyser (TC/EA)-IRMS. Mass spectrometry analyses will be performed at the University of Nottingham, United Kingdom.
Time frame: From baseline to week 7 (6 weeks of RT in duration)
Muscle protein breakdown (MPB) with the Combined Oral Stable Isotope Assessment of Muscle (COSIAM)
Before each measurement day, participants ingest 10 mg of stable isotopically labelled D-3-methylhistidine (D-3-MH) dissolved in 50 millilitres of water. When muscle proteins containing D-3-MH are degraded, D-3-MH is released into circulation. As D-3-MH cannot be reused for protein synthesis, D-3-MH can be used as a biomarker for muscle protein breakdown (MPB). The enrichment of labelled D-3-MH is then measured from the blood samples to assess MPB. The outcome will be expressed as the tracer dilution (k) rate of D3-3-MH and measured with repeated plasma sampling. 20-24 hours after the ingestion of D3-3MH, five plasma samples will be collected within three hours, each separated by 45 minutes. Plasma samples will be analysed at the University of Nottingham, United Kingdom.
Time frame: Baseline, Week 7
Change in whole-body skeletal muscle mass (SMM) with the Combined Oral Stable Isotope Assessment of Muscle (COSIAM)
First, a baseline urine sample is collected to measure D3-creatinine enrichment. Then, after the bladder is empty, participants consume 30 mg of labelled D3-creatine dissolved in 50 millilitres of water. The amount of D-3 creatine that spills over in urine samples after 24 hours of ingestion will then be used to determine the amount of D-3 creatine retained in the body by 24-hour urine collection. Then, as the amount of creatine-to-creatinine conversion remains similar in the total muscle pool, the comparison of both non-labelled and labelled creatinine can be used to estimate the whole-body muscle creatine pool from the urine samples gathered 48 to 72 hours post-ingestion. This enables the calculation of whole-body skeletal muscle mass with a simple equation and the following outcome will be expressed as kilograms (kg). Urine samples will be analysed at the University of Nottingham, United Kingdom.
Time frame: Baseline, Week 7
Change in muscle thickness (MT) of the elbow flexors after 6 and 12-week resistance training
MT of m. biceps brachii and m. brachialis is measured using a B-mode axial plane ultrasound (Venue Fit R4, GE Medical Systems, USA) with a L4-20t-RS linear-array probe (48,43 mm width).
Time frame: Baseline (test and retest), week 7, week 13
Change in lower and upper limb maximal strength after 6 and 12-week resistance training
Maximal voluntary concentric muscle strength of leg extensors is determined in a horizontal leg press device (David 210) via a one-repetition maximum (1RM) test. Moreover, the maximal voluntary concentric muscle strength of elbow flexors is also measured using barbell bicep curl performed in Scott bench. Maximum strength tests are performed according to the National Strength and Conditioning Association (NCSA) guidelines. Both concentric muscle strengths are expressed as kilograms (kg).
Time frame: Baseline (test and retest), week 7, week 13,
Change in corticoreticular excitability after resistance training with transcranial magnetic stimulation (TMS)
Electrical stimulation of the brachial plexus is performed during rest to elicit the maximum M-wave (M-max) of the biceps brachii. M-max is obtained by increasing the stimulator output intensity until the electromyography (EMG) response plateau. M-max is recorded using surface EMG. Next, single TMS pulses are delivered during tempo-controlled dynamic barbell bicep curls performed with a 30% load of one repetition maximum (1 RM). The TMS pulses are administered when the elbow joint flexion angle reaches 110 degrees. The stimulation intensity will be 100% of the maximum output. The protocol consists of two phases: the first involves four sets of five repetitions, followed by one set of 40 repetitions. Using TMS, investigators analyze the motor-evoked potential (MEP) amplitude, contralateral (cMEPs) and ipsilateral (iMEPs), the iMEP/cMEP amplitude ratio (ICAR), latency, and the silent period, all extracted from the EMG signal.
Time frame: Baseline (test and retest), week 7, week 13
Change in ribosome biogenesis
A portion of the VL muscle biopsies will be used for ribosomal analyses. Ribosome biogenesis and changes in messenger RNA and protein expression will be determined from the muscle biopsy samples by measuring ribosomal RNA and its regulators using real-time quantitative polymerase chain reaction (PCR) and proteomics.
Time frame: Baseline, week 7, week 13
Change in muscle fiber capillarization
A portion of the VL muscle biopsies will be used for immunohistochemical analysis. CD56 is used as an antibody for capillaries with a specific secondary fluorophore-labelled antibody. The structural quantification will be performed automatically using an artificial intelligence (AI)SDS PA-based software in Fiji.
Time frame: Baseline, week 7, week 13
Change in muscle fiber cross-sectional area (CSA) during the intervention period
A portion of the VL muscle biopsies will be used for immunohistochemical analysis. MANDYS8 antibody is used for staining muscle fiber borders with a specific secondary fluorophore-labelled antibody. Muscle fiber CSA will be quantified using an AI-based software in Fiji.
Time frame: Baseline, week 7, week 13
Change in myonuclear content of the muscle fibers
A portion of the VL muscle biopsies will be used for immunohistochemical analysis. PCM1 is used as an antibody for myonuclei with a specific secondary fluorophore-labelled antibody. Myonuclear content will be quantified using AI-based software in Fiji.
Time frame: Baseline, week 13
Change in satellite cell content during the intervention of the muscle fibers
A portion of the VL muscle biopsies will be used for immunohistochemical analysis. Pax7 is used as an antibody for satellite cells with a specific secondary fluorophore-labelled antibody. Satellite cell content will be quantified using AI-based software in Fiji.
Time frame: Baseline, week 13
Change in macrophage content of the muscle fibers
A portion of the VL muscle biopsies will be used for immunohistochemical analysis of macrophage content with the methods and primary (CD11b, CD206) and fluorophore-labelled secondary antibodies commonly utilized in our laboratory. Macrophage content will be quantified using AI-based software in Fiji.
Time frame: Baseline, week 7, week 13
Changes in anaerobic enzymes
Will be measured by Western blotting and Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE).
Time frame: Baseline, week 7, week 13
Changes in sarcoplasmic protein contents
Will be measured by Western blotting and SDS-PAGE.
Time frame: Baseline, week 7, week 13
Changes in multiomics during the intervention
Blood and muscle samples are used for the OMIC analyses. DNA extraction will be performed from blood and muscle samples in our Faculty. For genomic analysis, DNA samples will be sent to the Institute for Molecular Medicine Finland to produce single nucleotide polymorphisms using the advanced genotyping array (Illumina Infinium Global Screening Array-24v2.0 BeadChip). Then, quantitative genome-wide polygenic risk score (PRS) will be quantified using known genomic loci. Epigenetic analysis for DNA methylation will be assessed by Illumina's Infinium Methylation EPIC BeadChip (Illumina, San Diego, CA, USA). Transcriptomic profiling will be performed by RNA sequencing. Proteome profiling will be performed using large format difference in-gel electrophoresis (DiGE). Lastly, a high-throughput serum Nuclear Magnetic Resonance (NMR) metabolomics platform will be used for the absolute quantification of serum lipids and metabolite profiles.
Time frame: Baseline, week 13
Satellite cell isolation
From muscle biopsy samples, satellite cells will be isolated, and fibroblast-free primary satellite cell cultures will be established using the methods recently applied in our laboratory. Cultures of differentiated myotubes can be later utilized in mechanistic studies to examine specific molecular networks revealed by OMIC analyses.
Time frame: Week 13
Change in whole body fat mass
Fat body mass (kg) is measured at morning after overnight fasting by bioimpedance device (InBody 770, Biospace Co. Seoul, Korea).
Time frame: Baseline (test and retest), week 7, week 13
Change in whole body fat-free mass
Fat-free body mass (kg) is measured at morning after overnight fasting by bioimpedance device (InBody 770, Biospace Co. Seoul, Korea)
Time frame: Baseline (test and retest), week 7, week 13
Change in whole-body volume (cm^3)
The 3D optical body (3DO) scan is used to measure whole-body volume, the volume of the body segments, and waist, hip, and thigh circumference. For 3DO, Fit3D ProScanner (Redwood City, CA, USA) is used.
Time frame: Baseline (test and retest), week 7, week 13, before and after 6-weeks of ET.
Change in blood count determined from the venous blood sample obtained in the morning after overnight fasting before, mid, and after 12-week resistance training
Full blood count is measured by hematology analyzer (Sysmex KX-21N, Sysmex Corp., Japan)
Time frame: Baseline (test and retest), week 7, week 13
Change in C-reactive protein (CRP) determined from the venous blood sample obtained in the morning after overnight fasting before, mid, and after 12-week resistance training
Serum CRP is measured by high-sensitivity ELISA kit (Quantikine HS, R\&D Systems, Minneapolis, USA).
Time frame: Baseline, week 7, week 13
Self-reported measure of physical activity
Investigated by the Global Physical Activity Questionnaire (GPAQ), a standardized 16-question questionnaire that assesses categories of low, moderate, and vigorous physical activity (in metabolic equivalent \[MET\] minutes per week) in three different domains: activity at work, travel to and from places, and leisure activities. Also, sedentary behavior (minutes per week) is assessed.
Time frame: Baseline, week 13
Sleep self-assessment
Investigated by The Pittsburgh Sleep Quality Index (PSQI) questionnaire which consists of questions of a four-point Likert scale (0-3), with higher scores representing greater sleep difficulties.
Time frame: Baseline, week 13
Self-report of eating disorder behaviors and attitudes
Investigated by the Eating Disorder Examination Questionnaire (EDE-Q), which assesses the extent, frequency, and severity of eating disorder-related behaviors on a seven-point Likert scale or occurrence over a 28-day period. Higher scores represent higher levels of eating disorders.
Time frame: Baseline, week 13
Self-estimated energy availability
Investigated by the Low Energy Availability Questionnaire (LEAF-Q for females, LEAM-Q for men) which identifies persons at risk for low energy availability by utilizing subsets of gastrointestinal symptoms, injury frequency, and menstrual dysfunction (in women). A score ≥8 indicates that an individual is at risk for low energy availability.
Time frame: Week 13
Self-measure of perceived stress
Investigated by Perceived Stress Scale (14 items); from 0 (never) to 4 (very often). The scores are obtained by reverse scoring the positively stated items (7 items) and then summing the points across all 14 items.
Time frame: Baseline, week 7, week 13
Recovery of muscle swelling after acute resistance exercise (RE)
The 3D optical body (3DO) scan is used to measure whole-body volume, the volume of the body segments, and waist, hip, and thigh circumference. For 3DO, Fit3D ProScanner (Redwood City, CA, USA) is used.
Time frame: Week 12: before and after the second last and the last training session, and once during the days in between
Recovery of muscle strength after acute resistance exercise (RE)
Maximal voluntary concentric muscle strength of leg extensors (kg) is determined in horizontal leg press device (David 210) via a one-repetition maximum (1RM) test. Maximum strength test is performed according to the NCSA guidelines.
Time frame: Week 12: before and after the second last and the last training session, and once during the days in between
Subjective muscle soreness after acute resistance exercise (RE)
Subjective muscle soreness is determined by a questionnaire and rated on a Likert scale of 0 (= no pain) to 5 (= maximum pain) for the overall muscle soreness of the quadriceps muscles during palpation of the muscle belly and walking up and down stairs, squatting, and sitting down.
Time frame: Week 12: before the second last and the last training session, and once during the days in between
Time to exhaustion (TTE)
TTE is the elapsed time from the beginning of the RAMP test to the point of test cessation. Test cessation is determined as the point at which the participant is unable to maintain a cadence above 60 rpm after one warning, despite heavy encouragement.
Time frame: Baseline, week 7 (post)
Change in maximal oxygen uptake
Maximal oxygen uptake (VO2max) is determined by expired gas analysis using breath-by-breath with a metabolic cart (Jaeger Vyntus TM CPX, CareFusion Germany 234 GmbH, Hoechberg, Germany) during an incremental RAMP test. VO2max is determined as the highest oxygen uptake over 30 seconds.
Time frame: Baseline, week 7 (post)
Change in the first ventilatory threshold
The first ventilatory threshold is determined by expired gas analysis using breath-by-breath with a metabolic cart (Jaeger Vyntus TM CPX, CareFusion Germany 234 GmbH, Hoechberg, Germany). The first ventilatory threshold is determined as the point during a RAMP test at which ventilatory equivalent (Ve/Vo2) begins to increase systematically. This point is determined graphically by plotting Ve/Vo2 onto the y-axis and oxygen consumption onto the x-axis.
Time frame: Baseline, week 7 (post)
Change in the second ventilatory threshold
The second ventilatory threshold is calculated by expired gas analysis using breath-by-breath with a metabolic cart (Jaeger Vyntus TM CPX, CareFusion Germany 234 GmbH, Hoechberg, Germany). The second ventilatory threshold is determined as the point during a RAMP test at which carbon dioxide equivalent (Ve/VCO2) begins to increase. This point is determined graphically by plotting Ve/VCO2 onto the y-axis, and oxygen consumption (ml/min/kg) to the x-axis.
Time frame: Baseline, week 7 (post)
Changes in cardiac output
Cardiac output will be measured with an impedance cardiograph (ICG) device (PhysioFlow, Manatec Biocmedical, Paris, France). ICG calculates cardiac output by calculating the change in transthoracic impedance during cardiac ejection, allowing the determination of stroke volume multiplied by heart rate also calculated by the ICG device.
Time frame: Baseline, week 7 (post)
Changes in stroke volume
Stroke volume will be measured with an impedance cardiograph (ICG) device (PhysioFlow, Manatec Biocmedical, Paris, France). Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle.
Time frame: Baseline, week 7 (post)
Changes in heart rate
Heart rate will be monitored continuously during both endurance testing, as well as endurance exercise sessions. The device used for heart rate monitoring is Polar Vantage V2 (Polar Electro Oy, Kempele, Finland) and heart rate will be assessed using a Polar H10 heart rate sensor (Polar Electro Oy, Kempele, Finland) attached with a chest wrap.
Time frame: Baseline, weeks 1-6 of ET, week 7 (post)
Changes in blood lactate concentration
Capillary blood samples will be taken from the fingertip after each movement economy interval, after an incremental RAMP test, and after the ET sessions during the first training week. Lactate concentrations (mmol/l) will be analysed with the EKF-diagnostics Biosen C-line device.
Time frame: Baseline, week 1 of ET, week 7 (post)
Changes in blood glucose concentration
Capillary blood samples will be taken from the fingertip after each movement economy interval, after an incremental RAMP test, and after ET sessions during the first training week. Glucose concentrations (mmol/l) will be analysed with the EKF-diagnostics Biosen C-line device.
Time frame: Baseline, week 1 of ET, week 7 (post)
Changes in hematocrit
Hematocrit, the relative amount of red blood cells in the blood (%), is measured from the blood samples taken from the fingertip using a hemoglobinometry (HemoCue Hb-801) device.
Time frame: Baseline, week 7 (post)
Changes in hemoglobin concentration
Hemoglobin concentrations (g/DL) are measured from the blood samples taken from the fingertip using a hemoglobinometry (HemoCue Hb-801) device.
Time frame: Baseline, week 7 (post)
Changes in respitatory exhange ratio (RER)
RER is calculated by dividing carbon dioxide (CO2) production by oxygen (O2) consumption, enabling the determination of relative utilization of aerobic adenosine triphosphate (ATP) production systems.
Time frame: Baseline, week 7 (post)
Changes in arterial oxygen saturation
Arterial oxygen saturation is calculated from an earlobe continuously during endurance testing, using a pulse oximeter.
Time frame: Baseline, week 7 (post)
Changes in subjective rating of perceived exertion (RPE)
RPE is determined with a modified scale of 0-10, in which 0 stands for no exertion and 10 for maximal exertion.
Time frame: Baseline, weeks 1-6 of ET, week 7 (post)
Aerobic threshold
Aerobic threshold is determined as the 0.3 mmol/l increase in lactate concentrations from the lowest value, to estimate appropriate training loads for movement economy testing in baseline and post measurements.
Time frame: Familiarization
Changes in movement economy
Movement economy is measured as the mean oxygen uptake relative to a given power (W) output. As the number of intervals is four in each movement economy test, loads will be increased after every interval. The load in the last interval is aimed to be below the aerobic threshold.
Time frame: Baseline, week 7 (post)
Blood pressure
Systolic and diastolic arterial pressure (mmHg) are measured with OMRON blood pressure monitor. Before measurement, participants are sitting still for 5 minutes. During measurement, participants are advised to sit still and avoid talking.
Time frame: Baseline, week 7 (post)
Changes in heart rate variability (HRV)
HRV, a variability in time intervals between R-R intervals, is determined with Polar Vantage V2 (Polar Electro Oy, Kempele, Finland) and Polar H10 heart rate sensors (Polar Electro Oy, Kempele, Finland).
Time frame: Baseline, week 7 (post)
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Immediately following publication. No end date.
Access criteria: Researchers who provide a methodologically sound proposal. Proposals should be directed to juha.ahtiainen@jyu.fi
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Jyvaskyla